Captrust Financial Advisors Glaukos Corp Transaction History

Captrust Financial Advisors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$59.53 - $85.11 $196,270 - $280,607	3,297 New	3,297 $262,000
Q2 2022 Aug 16, 2022	BUY	$34.86 - $63.77 $8,854 - $16,197	254 Added 17.12%	1,738 $79,000
Q1 2022 May 16, 2022	BUY	$44.33 - $57.82 $35,818 - $46,718	808 Added 119.53%	1,484 $86,000
Q4 2021 Feb 14, 2022	BUY	$40.27 - $56.99 $966 - $1,367	24 Added 3.68%	676 $30,000
Q3 2021 Nov 16, 2021	BUY	$47.43 - $84.23 $2,750 - $4,885	58 Added 9.76%	652 $31,000
Q2 2021 Aug 16, 2021	BUY	$73.06 - $97.7 $29,224 - $39,080	400 Added 206.19%	594 $50,000
Q1 2021 May 17, 2021	BUY	$70.43 - $97.42 $7,324 - $10,131	104 Added 115.56%	194 $16,000
Q4 2020 Feb 16, 2021	BUY	$48.9 - $75.26 $4,401 - $6,773	90 New	90 $7,000

354

50M

282K

401K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.28B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.